专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070042937A1 Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers 审中-公开
标题翻译： 2-氧戊二酸双加氧酶抑制剂作为γ珠蛋白诱导剂
公开(公告)号：US20070042937A1
公开(公告)日：2007-02-22
申请号：US10566625
申请日：2004-07-30
申请人： Stephen Klaus , Peter Ratcliffe
发明人： Stephen Klaus , Peter Ratcliffe
IPC分类号： A61K38/40 , A61K48/00 , A61K31/7072 , A61K31/19
CPC分类号： A61K31/7072 , A61K31/17 , A61K31/19 , A61K31/47 , Y02A50/411
摘要： The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g., β thalassemia and sickle cell disease.
摘要翻译：本发明提供增加受试者内源性珠蛋白表达，特别是γ-珠蛋白表达的方法。本发明还提供了用于该方法的化合物和药物。所述方法对于增加受试者的胎儿血红蛋白产生特别有用，并且可用于治疗各种疾病，例如β地中海贫血和镰状细胞病。

2. 发明申请

US20060276477A1 Treatment method for anemia 审中-公开
标题翻译：贫血治疗方法
公开(公告)号：US20060276477A1
公开(公告)日：2006-12-07
申请号：US11448326
申请日：2006-06-06
申请人： Stephen Klaus , Thomas Neff
发明人： Stephen Klaus , Thomas Neff
IPC分类号： A61K31/502 , A61K31/4745 , A61K31/4704
CPC分类号： A61K45/06 , A61K31/00 , A61K31/17 , A61K31/4365 , A61K31/44 , A61K31/47 , A61K31/4704 , A61K31/4725 , A61K31/473 , A61K31/4745 , A61K31/496 , A61K31/502 , A61K33/26 , A61K38/1816 , A61K2300/00
摘要： The present invention relates to improved methods for treating anemia. Methods and compounds useful for treating anemia, wherein the anemia treatment is associated with a lower risk of thrombosis or hypertension compared to that observed with rhEPO therapy, are provided.
摘要翻译：本发明涉及治疗贫血的改进方法。提供了用于治疗贫血的方法和化合物，其中与用rhEPO治疗观察到的相比，贫血治疗与血栓形成或高血压的风险相关。

3. 发明申请

US20060183695A1 Methods of increasing endogenous erythropoietin (EPO) 审中-公开
公开(公告)号：US20060183695A1
公开(公告)日：2006-08-17
申请号：US11405734
申请日：2006-04-17
申请人： Stephen Klaus , Al Lin , Thomas Neff , Qingjian Wang , Volkmar Guenzler-Pukall , Michael Arend , Lee Flippin , Alex Melekhov
发明人： Stephen Klaus , Al Lin , Thomas Neff , Qingjian Wang , Volkmar Guenzler-Pukall , Michael Arend , Lee Flippin , Alex Melekhov
IPC分类号： A61K38/04 , A61K31/502
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/496 , A61K31/63 , A61K38/1709 , C07K14/4702 , C07K14/505 , G01N33/746
摘要： The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

4. 发明申请

US20050032748A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same 审中-公开
标题翻译：用于抑制白细胞介素-12信号的治疗化合物及其使用方法
公开(公告)号：US20050032748A1
公开(公告)日：2005-02-10
申请号：US10909321
申请日：2004-08-03
申请人： J. Klein , Stephen Klaus , Anil Kumar , Baoqing Gong
发明人： J. Klein , Stephen Klaus , Anil Kumar , Baoqing Gong
IPC分类号： A61K31/00 , C07D473/04 , C07D473/06 , C07D487/04 , C07D495/04 , C07D513/04 , A61K31/675 , A61K31/519 , A61K31/522
CPC分类号： C07D473/04 , A61K31/00 , C07D473/06 , C07D487/04 , C07D495/04 , C07D513/04
摘要： Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N,N(R3) and S. Each R1, R2 and R3 is substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.
摘要翻译：发现具有与五元环结构稠合的六元环结构的新型杂环化合物可用于治疗和预防与受白细胞介素-12（“IL-12”）影响的紊乱相关的症状或表现，，例如，Th1细胞介导的疾病。治疗化合物，药学上可接受的衍生物（例如分解的对映异构体，非对映异构体，互变异构体，其盐和溶剂合物）或其前药具有以下通式：每个X，Y和Z独立地选自C （R 3），N，N（R 3）和S.每个R 1，R 2和R 3是取代或未取代的，并且独立地选自氢，卤素，氧代，C（1-20）烷基，C （1-20）羟基烷基，C（1-20）硫代烷基，C（1-20）烷基氨基，C（1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）氨基烷氧羰基，C（1 -20）氨基烷基，C（1-20）三氨基烷基，C（1-20）四氨基烷基，C（5-15）氨基三烷氧基氨基，C（1-20）烷基酰氨基，C（1-20））烷基酰氨基烷基，C（1-20）酰氨基烷基，C（1-20）乙酰氨基烷基，C（1-20）烯基，C（1-20）炔基，C（3-8）烷氧基，C（1-11）烷氧基烷基，和C（1-20）二烷氧基烷基。

5. 发明申请

US20050020487A1 Enhanced erythropoiesis and iron metabolism 有权
标题翻译：增强红细胞生成和铁代谢
公开(公告)号：US20050020487A1
公开(公告)日：2005-01-27
申请号：US10861590
申请日：2004-06-03
申请人： Stephen Klaus , Christopher Molineaux , Thomas Neff , Volkmar Guenzler-Pukall , Ingrid Langsetmo Parobok , Todd Seeley , Robert Stephenson
发明人： Stephen Klaus , Christopher Molineaux , Thomas Neff , Volkmar Guenzler-Pukall , Ingrid Langsetmo Parobok , Todd Seeley , Robert Stephenson
IPC分类号： A61K31/00 , A61K31/165 , A61K31/395 , A61P7/06 , A61K38/16
CPC分类号： C07D217/24 , A61K31/00 , A61K31/165 , A61K31/17 , A61K31/395 , A61K31/472 , C07C275/40
摘要： The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
摘要翻译：本发明涉及用于调节或增强红细胞生成和铁代谢以及用于治疗或预防慢性疾病的铁缺乏和贫血的方法和化合物。

6. 发明申请

US20070004627A1 Compounds and methods for treatment of cancer 有权
标题翻译：化合物和治疗癌症的方法
公开(公告)号：US20070004627A1
公开(公告)日：2007-01-04
申请号：US11455199
申请日：2006-06-15
申请人： Todd Seeley , David Liu , Stephen Klaus
发明人： Todd Seeley , David Liu , Stephen Klaus
IPC分类号： A61K38/54 , A61K31/19 , A61K31/195
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/19 , A61K31/195 , A61K31/63 , A61K38/16
摘要： The invention relates to methods and compounds for treating or preventing cancer. Methods for treating or preventing cancer, for inhibiting tumor growth, reducing tumor volume, inhibiting tumor progression, inhibiting metastasis, and improving survival are provided herein.
摘要翻译：本发明涉及治疗或预防癌症的方法和化合物。本文提供了治疗或预防癌症，抑制肿瘤生长，减少肿瘤体积，抑制肿瘤进展，抑制转移和改善生存的方法。

7. 发明申请

US20060251638A1 Cytoprotection through the use of hif hydroxylase inhibitors 审中-公开
标题翻译：通过使用hif羟化酶抑制剂进行细胞保护
公开(公告)号：US20060251638A1
公开(公告)日：2006-11-09
申请号：US10554450
申请日：2004-06-04
申请人： Volkmar Guenzler-Pukall , Stephen Klaus , David Liu , Todd Seeley
发明人： Volkmar Guenzler-Pukall , Stephen Klaus , David Liu , Todd Seeley
IPC分类号： A61K38/44 , A61K38/22
CPC分类号： A61K31/63 , A61K31/00 , A61K31/4745
摘要： The invention relates to methods for conferring cytoprotection, or for inducing a cytoprotective effect, by administering a compound that inhibits HIF hydroxylase. Compounds for use in these methods are also provided.
摘要翻译：本发明涉及通过施用抑制HIF羟化酶的化合物来赋予细胞保护作用或诱导细胞保护作用的方法。还提供了用于这些方法的化合物。

8. 发明申请

US20060178317A1 Methods of increasing endogenous erythropoietin (EPO) 审中-公开
公开(公告)号：US20060178317A1
公开(公告)日：2006-08-10
申请号：US11406484
申请日：2006-04-17
申请人： Stephen Klaus , Al Lin , Thomas Neff , Qingjian Wang , Volkmar Guenzler-Pukall , Michael Arend , Lee Flippin , Alex Melekhov
发明人： Stephen Klaus , Al Lin , Thomas Neff , Qingjian Wang , Volkmar Guenzler-Pukall , Michael Arend , Lee Flippin , Alex Melekhov
IPC分类号： A61K38/04 , A61K31/4745
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/17 , A61K31/4375 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/472 , A61K31/4738 , A61K31/496 , A61K31/63 , A61K38/1709 , C07K14/4702 , C07K14/505 , G01N33/746
摘要： The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

9. 发明申请

US20050049262A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same 审中-公开
标题翻译：用于抑制白细胞介素-12信号的治疗化合物及其使用方法
公开(公告)号：US20050049262A1
公开(公告)日：2005-03-03
申请号：US10918709
申请日：2004-08-16
申请人： J. Klein , Stephen Klaus , Anil Kumar , Baoqing Gong
发明人： J. Klein , Stephen Klaus , Anil Kumar , Baoqing Gong
IPC分类号： A61K31/00 , C07D239/54 , C07D473/04 , C07D473/06 , C07D473/10 , C07D487/04 , C07D495/04 , C07D513/04 , A61K31/519 , A61K31/522
CPC分类号： C07D239/54 , A61K31/00 , C07D473/04 , C07D473/06 , C07D473/10 , C07D487/04 , C07D495/04 , C07D513/04
摘要： Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by lnterleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S. Each R1, R2 and R3 is substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraaminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.
摘要翻译：发现具有与五元环结构稠合的六元环结构的新型杂环化合物可用于治疗和预防与白细胞介素-12（“IL-12”）受细胞内信号传导的疾病相关的症状或表现，例如，例如，Th1细胞介导的疾病。治疗化合物，药学上可接受的衍生物（例如分解的对映异构体，非对映异构体，互变异构体，其盐和溶剂合物）或其前药具有以下通式：每个X，Y和Z独立地选自C （R 3），N，N（R 3）和S.每个R 1，R 2和R 3是取代或未取代的，并且独立地选自氢，卤素，氧代，C（1-20）烷基，C （1-20）羟基烷基，C（1-20）硫代烷基，C（1-20）烷基氨基，C（1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）氨基烷氧羰基，C（1 （1-20）氨基烷基，C（1-20）四氨基烷基，C（5-15）氨基三烷氧基氨基，C（1-20）烷基酰氨基，C（1-20）烷基氨基烷基，C（1-20））烷基酰氨基烷基，C（1-20）酰氨基烷基，C（1-20）乙酰氨基烷基，C（1-20）烯基，C（1-20）炔基，C（3-8）烷氧基，C（1-11）烷氧基烷基，和C（1-20）二烷氧基烷基。

10. 发明申请

US20120197788A1 TRANSACTION PROCESSING ENGINE FOR BILL PAYMENT TRANSACTIONS AND THE LIKE 审中-公开
标题翻译：交易处理发票用于付款交易和类似交易
公开(公告)号：US20120197788A1
公开(公告)日：2012-08-02
申请号：US13358276
申请日：2012-01-25
申请人： Hemal Sanghvi , Sridhar Ramalingam , Rich Ampleman , Robert Hoffman , Pauline Ow , Stephen Klaus , Gidget A. Hall
发明人： Hemal Sanghvi , Sridhar Ramalingam , Rich Ampleman , Robert Hoffman , Pauline Ow , Stephen Klaus , Gidget A. Hall
IPC分类号： G06Q20/14
CPC分类号： G06Q20/102 , G06Q30/02
摘要： A payment processing network operator obtains, from customer service providers, a first plurality of messages specifying a plurality of bill payments to a plurality of biller entities. Said first plurality of messages specifies, for each of the bill payments, an amount and an intended one of the biller entities to be paid. Based on the first plurality of messages, the operator of the payment processing network dispatches, to the plurality of biller entities, a second plurality of messages to initiate the plurality of bill payments. The operator of the payment processing network obtains data that specifies when at least some of the first plurality of messages are to be obtained and/or when at least some of the second plurality of messages are to be dispatched. Obtaining the first plurality of messages and/or scheduling dispatching the second plurality of messages are carried out in accordance with the data.
摘要翻译：支付处理网络运营商从客户服务提供商获得指定多个账单支付给多个账单实体的第一多个消息。所述第一多个消息针对每个账单支付指定要支付的账单实体的金额和期望的一个。基于第一多个消息，支付处理网络的运营商向多个账单实体发送第二多个消息以启动多个账单支付。支付处理网络的运营商获得指定何时要获得第一多个消息中的至少一些的数据和/或当要发送第二个多个消息中的至少一些消息时的数据。根据数据执行获取第一多个消息和/或调度第二多个消息的调度。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式